• PP 3: Identity, Control Role, and Evidence Limits

  2026-10-15

  PP 3, or 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, is documented by APExBIO as a research use only chemical intended as a negative control for the Src kinase inhibitor PP 2. The available product information supports a narrow interpretation of its comparator role, but does not establish independent target engagement, biological inactivity, selectivity, potency, or study-specific outcomes.

• Viperin, nsp8 and Coronavirus Replication

  2026-10-15

  A literature-focused analysis of a 2026 study reporting that viperin restricts porcine deltacoronavirus through direct interaction with coronavirus nsp8, complementing rather than simply duplicating ddhCTP-mediated interruption of viral RNA synthesis.

• Dibutyryl-cAMP: Identity, Mechanism and Scope

  2026-10-14

  Dibutyryl-cAMP, sodium salt, also termed DBcAMP sodium salt, is presented by APExBIO as a cell-permeable, stable cAMP analog intended to perturb cAMP-dependent signaling. The available material supports a product-identity and mechanism overview, but it does not provide an identity-matched research paper, quantitative outcomes, or independent evidence for selectivity, potency, or performance in a particular model.

• EdU Imaging and HCC Proliferation: Evidence Boundaries

  2026-10-14

  EdU imaging provides a direct proxy for DNA synthesis during S phase, but an EdU-positive signal is not by itself equivalent to cell division or treatment response. The supplied HCC study implicates DRG1 in malignant proliferation and lenvatinib resistance, yet it does not establish that the APExBIO product was used or validate the product clinically.

• Filipin III and Cholesterol-Centered Tumor Biology

  2026-10-13

  Filipin III is a cholesterol-binding polyene macrolide antibiotic used conceptually for membrane sterol visualization. The supplied PID1 study links myeloid cholesterol–oxysterol metabolism to macrophage state and antitumor immunity, but it does not establish that Filipin III was used or that filipin-based imaging can identify the reported oxysterols or prove the proposed pathway.

• CDK9 Inhibitor A3294: Identity and Evidence Scope

  2026-10-13

  A source-limited overview of APExBIO’s CDK9 inhibitor A3294, its documented molecular target and conceptual research scope, and the limitations imposed by the absence of a matched reference paper.

• What PEI Studies Reveal About mRNA Delivery

  2026-10-12

  A source-grounded overview of how branched polyethyleneimine molecular weight and cell type influenced reporter-mRNA delivery, with boundaries around applying those findings to ARCA EGFP mRNA (5-moUTP) or clinical systems.

• AEBSF.HCl and Necroptosis: Evidence Gaps

  2026-10-12

  The supplied evidence supports a mechanistic model in which MLKL polymerization contributes to lysosomal membrane permeabilization and cathepsin B-dependent necroptosis, but it does not show that AEBSF.HCl produces or modifies this effect. Supplier-described findings on amyloid precursor protein cleavage and leukemic cell lysis should therefore be kept separate from the published necroptosis study.

• tFUS, Nespas, and SHP2 in Ischemic Stroke

  2026-10-10

  This study links low-intensity transcranial focused ultrasound stimulation with reduced post-stroke neuroinflammation through the Nespas/miR-383-3p/SHP2 axis and downstream NLRP3 inflammasome activity. Its combination of an ischemic stroke model, microglial experiments, transcriptomic analysis, and pathway perturbation provides a mechanistic framework, while the animal and cell-based evidence remains preliminary for clinical translation.

• LC–MS/MS Maps GS-441524 Prodrug Conversion

  2026-10-09

  A January 2026 Microchemical Journal study used LC–MS/MS to distinguish a novel GS-441524 prodrug, NGP-1, from its active-metabolite-related product, GS441, across in vitro matrices and a rat pharmacokinetic model. The findings support a staged conversion concept involving gastric conditions, hepatic metabolism, and blood-associated hydrolysis, while remaining preclinical and insufficient to establish human efficacy or safety.

• SU6656: From Src Biology to Translational Strategy

  2026-10-09

  A source-grounded perspective on SU6656, Src-family kinase biology, hiPSC-derived platelet manufacturing, and preclinical radiotherapy sensitization. The article separates established findings from forward-looking translational hypotheses and outlines how researchers can evaluate pathway-specific evidence without overextending the data.

• Bifendate (DDB): Evidence, Uses, and Limits

  2026-10-08

  Bifendate (DDB) is a synthetic Schisandrin C derivative described as a hepatoprotective agent, lipid-metabolism regulator, and autophagy inhibitor. However, the supplied evidence is largely product-level information, while the cited peer-reviewed study examines the different compound praeruptorin A. This overview separates direct evidence from mechanistic claims, identifies conceptual research applications, and defines important limits on interpretation.

• From Protein Complexes to Translational Insight

  2026-10-08

  A source-grounded perspective on how protein-complex mapping can strengthen translational research, using the 2026 Trichoderma–peanut study as an anchor and the Protein A/G Magnetic Co-IP/IP Kit as a conceptual workflow fit.

• Eicosapentaenoic Acid: Evidence and Research Context

  2026-10-07

  Eicosapentaenoic Acid (EPA) is an omega-3 polyunsaturated fatty acid studied in cardiovascular and inflammatory biology. The supplied evidence supports research interest in membrane lipid remodeling and vascular mechanisms, while a recent arachidonic acid vaccine study offers relevant mechanistic context but does not establish that EPA produces the same immune effects.

• Berberine, SIRT6–AMPK, and Atrial Fibrillation

  2026-10-07

  Zhou and colleagues identify SIRT6–AMPK signaling as a mechanistic link between angiotensin II stress, NLRP3 inflammasome activation, atrial remodeling, and atrial fibrillation susceptibility. Their integrated human-sample, bioinformatics, murine-model, and genetic-manipulation evidence supports berberine as a preclinical pathway modulator, while leaving clinical efficacy and pathway specificity unresolved.

8039 records 1/536 page Next 12345 下5页 Last page